-
The first START site in New York launches a new strategic partnership to provide cutting-edge cancer research.
Dec 16, 2025
-
Built directly into the elluminate ecosystem, the agents combine governed data with explainable intelligence to accelerate decisions
Dec 9, 2025
-
CluePoints, provider of leading statistical and AI-driven software solutions, has won the ‘Best Contract Research Organization– Specialist Providers’ category at the 2025 Scrip Awards.
Dec 11, 2025
-
4D Path, a company dedicated to personalizing cancer care through a novel, physics-inspired approach to predicting tumor response to therapy, today announced a collaboration with AMD and Oracle to advance predictive oncology and accelerate clinical trials. Using AMD EPYC™ CPUs on Oracle Cloud Infrastructure (OCI), 4D Path’s QPOR™ platform—a physics-informed, AI-driven, deterministic software engine—can convert routine biopsy images into interpretable biomarkers of tumor and immune response faster and at lower cost.
Dec 9, 2025
-
New York Gastroenterology Associates, LLP (NYGA), New York City’s leading independent gastroenterology practice, is working with Proscia, a pathology AI company, to advance its standard of excellence
Dec 8, 2025
-
New Scale Technologies is announcing the availability of the new DART linear actuator and stage platform.
The DART line is designed to meet the needs of photonic instruments and life science companies looking for smart motion solutions with longer travel and lower cost for high-volume applications. The DART Smart Linear Actuator builds on New Scale’s proprietary SQUIGGLE® technology, offering a greater range of motion and higher force.
Dec 8, 2025
-
4D Path, a company dedicated to personalizing cancer care through a novel, physics-inspired approach to predicting tumor response to therapy, today announced that the company’s Q-Plasia OncoReader (QPOR™) platform has successfully predicted treatment response in patients with early-stage triple-negative breast cancer (TNBC) using digitized baseline biopsy images. Analysis conducted within the Translational Breast Cancer Research Consortium (TBCRC) 030 clinical trial represents the first demonstration of a statistical physics and tumor biology-based computational biomarker predicting post-treatment outcomes from pre-treatment tissue alone, without any clinical or molecular inputs.
Dec 2, 2025
-
Compliance with independent security standards comes as Proscia accelerates digital pathology deployments at scale
Dec 2, 2025
-
Collaboration to support value-based reimbursement models for GLP-1 receptor agonists, optimizing patient outcomes, increasing markets, and healthcare sustainability.
Nov 24, 2025
-
Nov 19, 2025
-
New state-of-the-art facility in Philadelphia provides integrated lab and collaboration space along with tailored guidance to help move advanced therapies from early research to clinical readiness
Nov 17, 2025
-
CluePoints, provider of leading statistical and AI-driven software solutions, has announced Sylviane de Viron, its Data and Knowledge Manager, has been appointed to the Applied Clinical Trials (ACT) editorial advisory board.
Nov 10, 2025
-
• Ready-to-use solution, developed in collaboration with GenScript, offers rapid and reliable quantification of His-tagged proteins
• Broadens Amperia’s applications across recombinant protein research, screening, and development
• Abselion to showcase kit alongside Amperia platform at PEGS Europe in Lisbon, Portugal from 11–13 November
Nov 9, 2025
-
Baylor Genetics, a clinical diagnostic laboratory at the forefront of genetic testing, today announced it was awarded a multi-year national contract from the United States Department of Veterans Affairs (VA) to deliver pharmacogenomic (PGx) testing and germline genetic testing services, which includes hereditary cancer testing to veterans across the VA healthcare system.
Nov 9, 2025
-
As of Nov. 1, 2025, Medi-Cal (California’s Medicaid) has begun covering whole genome sequencing (WGS). This landmark coverage expands access to WGS for patients across California.
Nov 2, 2025
-
Nov 2, 2025
-
• Offers UK academic research institutions improved access to Primerdesign’s real-time PCR assays and reagents with reliable, fast and local support
• SLS to showcase Primerdesign portfolio at Lab Innovations in Birmingham, UK (29–30 October)
Oct 29, 2025
-
EazeBio has announced a strategic partnership with the University of California, Santa Cruz to advance and commercialize a groundbreaking instrument-free diagnostic platform.
Oct 28, 2025
-
Spaarne Gasthuis, a top clinical teaching hospital serving part of the Greater Amsterdam region, is fully digitizing its pathology practice with Concentriq® AP-Dx* from Proscia®. With this software platform, the hospital will empower its pathologists to play an even more significant role in guiding personalized treatment decisions for hundreds of thousands of patients each year.
Oct 26, 2025
-
Molsid, a French biotech company, announces the successful completion of the clinical performance study for ResiScreen® Staph, an innovantive solution for faster detection of staphylococcal beta-lactamase. Powered by Molsid's patented SmartID® fluorescent biotracer technology, ResiScreen® Staph reaffirms the company's mission to deliver next-generation diagnostic technologies to support clinical laboratories in the contention of antimicrobial resistance.
Oct 26, 2025